Silvacx Team in the local press (30 April 2020)

"Bensheimer entwickeln Impfplattform"

Rolf Brockmeyer joined the Silvacx Team too (1 February 2020)

Rolf Brockmeyer strengthens the Silvacx Team with his extraordinary expertise in Regulartory Affairs. Rolf has a PhD in pharmacy and worked for decades a Bayer AG. Welcome to the team!

Thomas Kessler joined the Silvacx Team (1 Januar 2020)

Today Thomas Kessler has officially joined the Silvacx Team. He takes care of business development, marketing and investor relations. With his complementary knowledge (chemistry and business administration) he understands both "worlds" very well. Welcome and enjoy our journey!

Silvacx is one of eight finalists of the BioRiver Boost! 2019 (4 October 2019)

Silvacx has been selected as one of eight finalists of the BioRiver Boost! 2019. We'll give a pitch presentation on 15 October 2019 at Miltenyi Biotec, Bergisch Gladbach. More information about this event can be found here.

Take the opportuity and meet us in Bergisch Gladbach!

Life Science Inkubator (LSI) Bonn for the first time supports pharma industry spin-out  (1 February 2018)

Merck spin-off Silvacx receives seed financing of almost EUR 2 million

Bonn, Germany, February 1, 2018 -- Life Science Inkubator GmbH (LSI) for the first time supports a research project originating from a pharma company. The project called Silvacx is a spin-off from Merck AG and is developing novel delivery technologies for cancer immunotherapy. The Silvacx team headed by Armin Kuebelbeck (previously Merck KGaA) also received public funding totaling EUR 1.93 million from the state of North Rhine-Westphalia´s Ministry of Culture and Science, which will be dedicated to further research and development activities over the next three years. Subsequently, clinical evaluation of the platform technology is planned.

The Silvacx technology licensed from Merck is based on silicon dioxide nanoparticles, which will be used as...

read the full article